广州迈普再生医学科技股份有限公司 2025 年半年度报告全文 广州迈普再生医学科技股份有限公司 2025 年半年度报告 公告编号：2025-059 2025 年 8 月 22 日 1 广州迈普再生医学科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 公司负责人袁玉宇、主管会计工作负责人骆雅红及会计机构负责人(会计 主管人员)孙治国声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中如有涉及未来的计划、业绩预测等前瞻性陈述，均不构成公司对 任何投资者及相关人士的实质承诺，投资者及相关人士均应对此保持足够风 险认识，并且应当理解计划、预测与承诺之间的差异，最后公司敬请投资者 注意投资风险。 公司需遵守《深圳证券交易所上市公司自律监管指引第 4 号——创业板行 业信息披露》"第三章生物产业"之"第二节医疗器械业务"的披露要求。 请投资者注意阅读本报告"第三节 管理层讨论与分析"之"十、公司面临 ...

董事会决议公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-058 广州迈普再生医学科技股份有限公司 第三届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 广州迈普再生医学科技股份有限公司（以下简称"公司"）第三 届董事会第十三次会议于 2025 年 8 月 20 日上午 10:30 以现场和通讯 相结合的方式在公司会议室召开。本次会议通知已于 2025 年 8 月 9 日以邮件的方式发出。会议应出席董事 9 人，实际出席董事 9 人，其 中，袁玉宇先生、骆雅红女士、陈建华先生以通讯方式出席会议。本 次会议由董事长袁玉宇先生召集并主持，公司全体董事出席了会议， 全体高级管理人员列席了会议。本次会议的召集、召开和表决程序符 合国家有关法律、行政法规及《广州迈普再生医学科技股份有限公司 章程》（以下简称"《公司章程》"）的规定，会议形成的决议合法 有效。 二、董事会会议审议情况 本次会议以记名方式投票表决，审议并通过了以下事项： （一）审议通过《关于<公司 2025 年半年度报告全文>及摘要的 ...

Group 1 - The stock price of Maipu Medical experienced fluctuations on August 19, closing at 85.68 yuan, down 1.29% from the previous trading day [1] - The trading volume on that day was 12,560 hands, with a transaction amount of 1.09 billion yuan, and a price fluctuation of 5.28% [1] - Maipu Medical operates in the medical device industry, focusing on the research and production of implantable medical devices in neurosurgery and oral fields, with products including artificial dura mater and craniofacial repair systems [1] Group 2 - On August 18, the company announced that shareholder Guoshou Chengda completed a reduction plan, selling a total of 1.9956 million shares, accounting for 2.9958% of the company's total share capital [1] - After the reduction, Guoshou Chengda's shareholding ratio decreased to 1.9093% [1] - On August 19, the net inflow of main funds was 6.2331 million yuan, representing 0.13% of the circulating market value, while the cumulative net outflow over the past five trading days was 3.0485 million yuan, accounting for 0.06% of the circulating market value [1]

南方财经8月19日电，迈普医学(301033.SZ)公告，首发前股东国寿成达于2025年7月14日至8月15日期间 通过集中竞价交易和大宗交易方式合计减持1,995,582股，占公司总股本的2.9958%。其中，集中竞价交 易减持时间为2025年7月14日至7月22日，减持均价为61.53元/股，减持665,194股，占总股本0.9986%； 大宗交易减持时间为2025年7月15日至8月15日，减持均价为65.35元/股，减持1,330,388股，占总股本 1.9972%。此次减持完成后，国寿成达持有公司股份从3,267,436股减少至1,271,854股，占公司总股本的 比例从4.9120%降至1.9093%。 ...

Policy Developments - The National Medical Insurance Administration held a mid-year meeting in Xi'an, focusing on enhancing the development of medical institutions and the pharmaceutical industry, ensuring public health, and improving the basic medical insurance system [2] Drug and Device Approvals - Heng Rui Medicine's application for the marketing license of Haequibopamine tablets has been accepted by the National Medical Products Administration, aimed at treating chemotherapy-induced thrombocytopenia in adult patients [4] - Dongfang Bio and its subsidiaries have obtained multiple medical device registration certificates, including flu virus antigen test kits and other diagnostic tools, enhancing the company's product range and market competitiveness [5] - Zhifei Biological's clinical trial application for a component DTP vaccine for adolescents and adults has been accepted, with significant market potential as no similar vaccine is currently approved for this demographic [6] Financial Reports - Fuyuan Medicine reported a 1.30% decrease in revenue to 1.634 billion yuan and a 7.83% decline in net profit to 268 million yuan for the first half of 2025 [8] - Jiuyuan Gene achieved total revenue of 638.8 million yuan and a net profit of 90.2 million yuan, with over 10% growth in orthopedic product sales despite industry challenges [9] - Kangzhe Pharmaceutical reported a 10.8% increase in revenue to approximately 4 billion yuan and a 3.1% rise in net profit to about 930 million yuan for the first half of 2025 [11] Capital Market - Kening Bio completed a multi-million A-round financing to support clinical research for its core pipelines targeting osteoarthritis and dry eye syndrome, with plans to start overseas clinical trials in 2026 [13] Industry Events - A new decision-making framework called FRAME was proposed by a research team from the Chinese Academy of Sciences, showing significant improvements in medical insights using large language models [15] - Ant Group launched initiatives to combat fake medical advertisements through its AI health application, aiming to protect public interests amid increasing regulatory scrutiny [16] Shareholder Actions - Guoshou Chengda has reduced its stake in Maipu Medical by 2.9958%, completing its share reduction plan [18] - Sichuang Medical's vice president resigned for personal career planning reasons, indicating potential changes in company leadership [19]

Policy Developments - The National Medical Insurance Work Mid-Year Symposium was held in Xi'an, Shaanxi, on August 15, 2025, focusing on the progress and future priorities of medical insurance work, emphasizing the need for empowerment of medical institutions and innovation in the pharmaceutical industry [1] Drug and Device Approvals - Heng Rui Medicine announced that its application for the marketing authorization of Haqubopam Ethanolamine Tablets has been accepted by the National Medical Products Administration, aimed at treating chemotherapy-induced thrombocytopenia in adult patients [2] - Dongfang Bio reported that it and its subsidiaries obtained multiple medical device registration certificates, including flu virus antigen test kits and various antibody test kits, enhancing its product range and market competitiveness [3] - Zhifei Biological's clinical trial application for a component DTP vaccine for adolescents and adults has been accepted, with significant market potential as no similar vaccine is currently approved for this demographic in China [4] Financial Reports - Fuyuan Medicine reported a 1.30% decrease in revenue to 1.634 billion yuan and a 7.83% decline in net profit to 268 million yuan for the first half of 2025 [5] - Jiuyuan Gene announced total revenue of 638.8 million yuan and a net profit of 90.2 million yuan, facing challenges from policy changes and internal adjustments, but showing resilience with over 10% growth in orthopedic product sales [6] - Kangzhe Pharmaceutical reported a 10.8% increase in revenue to approximately 4 billion yuan and a 3.1% rise in net profit to about 930 million yuan for the first half of 2025 [7] Capital Market - Kegong Bio completed a multi-million A-round financing, which will support its clinical research for core pipelines targeting osteoarthritis and dry eye syndrome, with plans to start overseas clinical trials in 2026 [8] Industry Developments - A new decision-making framework for medical large models, FRAME, was proposed by a research team from the Chinese Academy of Sciences, showing significant improvements in medical insights compared to traditional methods [9] - Ant Group has launched initiatives to combat fake medical advertisements through its AI health application, AQ, which includes features for users to verify medical claims [10] Shareholder Actions - Guoshou Chengda has completed a reduction of 2.9958% of its shares in Maipu Medical, reducing its holdings to 1.9093% of the total share capital [11] - Sichuan Medical's Vice President resigned for personal career planning reasons, stepping down from all positions within the company [12]

Mergers and Acquisitions - Jingjiawei plans to invest 220 million yuan to acquire a controlling stake in Chengheng Microelectronics, entering the edge AI chip sector [1] - Aerospace Changfeng intends to publicly transfer 55.45% of its stake in Aerospace Parker, with an assessed value of 201 million yuan [2] - Kangping Technology has signed an agreement to acquire a controlling stake in Suzhou Lingchen, focusing on core components in intelligent equipment [3] Financial Performance - Zhifei Biological reported a net loss of approximately 600 million yuan in the first half of 2025, with revenue declining by 73.06% to 4.919 billion yuan [4] - AVIC Shenyang Aircraft Company expects a 30% decrease in net profit for the first half of 2025, with revenue around 14.628 billion yuan, down 32.35% [5] - Jingjiawei announced a net loss of 87.61 million yuan in the first half of 2025, with revenue falling by 44.78% to 193 million yuan [6] - Jiao Cheng Ultrasonic reported a 1005% increase in net profit for the first half of 2025, reaching 58.04 million yuan, with revenue up 32.50% to 323 million yuan [7] Shareholding Changes - Myp Medical announced that Guoshou Chengda has reduced its stake in the company by nearly 3%, totaling 199,560 shares [8] - Xishanghai disclosed that shareholder Huijia Chuangtou plans to reduce its stake by up to 1%, not exceeding 134,550 shares [9][10] Investment Agreements - Longsheng Technology's subsidiary plans to invest approximately 200 million yuan to establish a lightweight component production base for new energy vehicles in Chongqing [11]

Core Insights - A total of 12 listed companies have disclosed share reduction plans, with no companies announcing share increases on the same day [1] Group 1: Share Reduction Details - Lianming Co., the controlling shareholder plans to reduce no more than 3.00% of the company's shares [2] - Geng Shanghai's shareholder Huijia Chuangtou intends to reduce no more than 1% of the company's shares [2] - Jinhui Co.'s shareholder Green Mine Fund plans to reduce no more than 3% of the company's shares [2] - Wanlang Magnetic Plastic's shareholder Ouyang Ruiqun intends to reduce no more than 2% of the company's shares [2] - Maipu Medical's Guoshou Chengda has cumulatively reduced 2.9958% of the company's shares [2] - Nanya New Materials' directors, including Zhang Dong, have reduced their shares [2] - Maihe Co.'s shareholder Wang Xuping plans to reduce no more than 150,000 shares [2] - Jujia Optoelectronics' actual controller and chairman Pan Huarong intends to reduce no more than 1% of the company's shares [2] - Huashu Media's Zhejiang Yitong Media plans to reduce no more than 1% of the company's shares [2] - Haizhu Co.'s shareholders Park Huahui and Zhongwen Chantu plan to collectively reduce no more than 5.36% of the company's shares [2] - Zhonghuan Environmental Protection's Jintong Anyi intends to reduce no more than 3.55% of the company's shares [2] - Haichuan Intelligent's shareholders Wu Guifang and Zheng Xuefen plan to collectively reduce no more than 6% of the company's shares [2]

Summary of Key Points Core Viewpoint - As of August 18, a total of 12 listed companies have disclosed share reduction plans, with no companies announcing share increases on the same day [1]. Group 1: Companies with Share Reduction Plans - Lianming Co., Ltd. plans to reduce its holdings by up to 3.00% of the company's shares [2]. - Xishanghai's shareholder Huijia Chuangtou intends to reduce its stake by no more than 1% [2]. - Jinhui Co., Ltd.'s shareholder Green Mining Fund plans to reduce its holdings by up to 3% [2]. - Wanlang Magnetic Plastic's shareholder Ouyang Ruiqun intends to reduce its stake by no more than 2% [2]. - Maipu Medical's shareholder Guoshou Chengda has cumulatively reduced its holdings by 2.9958% [2]. - Nanya New Materials' board member Zhang Dong and others are reducing their shares [2]. - Maihe Co., Ltd.'s shareholder Wang Xuping plans to reduce up to 150,000 shares [2]. - Juzan Optoelectronics' actual controller and chairman Pan Huarong intends to reduce no more than 1% of the company's shares [2]. - Huashu Media's Zhejiang Yitong Media plans to reduce its stake by no more than 1% [2]. - Haikan Co., Ltd.'s shareholders Park Huahui and Zhongwen Chantu plan to collectively reduce up to 5.36% [2]. - Zhonghuan Environmental's Jintong Anyi intends to reduce its holdings by no more than 3.55% [2]. - Haichuan Intelligent's shareholders Wu Guifang and Zheng Xuefen plan to collectively reduce up to 6% [2].

每经AI快讯，8月18日，迈普医学(301033.SZ)公告称，公司股东国寿成达（上海）健康产业股权投资中 心（有限合伙）已完成减持计划。国寿成达于7月14日-8月15日通过集中竞价和大宗交易方式，合计减 持1,995,582股，占公司当前总股本的2.9958%。减持后，国寿成达持有公司股份1,271,854股，占总股本 的1.9093%。 ...